Literature DB >> 660467

Fluorometric TLC determination of free and conjugated propranolol, naphthoxylactic acid, and p-hydroxypropranolol in human plasma and urine.

Y Garceau, I Davis, J Hasegawa.   

Abstract

Sensitive, specific, and reproducible TLC methods are described for the determination of propranolol and its major metabolites in humans, conjugated propranolol, free and conjugated naphthoxylactic acid, and free and conjugated p-hydroxypropranolol. The drug or metabolites are extracted from plasma or urine with ether and applied to TLC plates of silica gel or microcrystalline cellulose. After development, the plates are scanned in a spectrodensitometer equipped to measure fluorescence in the UV and blue regions of the light spectrum. Quantitation is achieved by comparing the areas under the peaks obtained from the unknowns to those obtained from standards applied to the same plate. Limits of quantitation in plasma are: free propranolol, 2 ng/ml; free p-hydroxypropranolol, 10 ng/ml; conjugated propranolol, 15 ng/ml; total (free and conjugated) naphthoxylactic acid, 25 ng/ml; and conjugated p-hydroxypropranolol, 50 ng/ml. These methods were used to obtain plasma level data in a volunteer after one single dose of propranolol and in patients under propranolol therapy. The Rf values of some known metabolites of propranolol obtained in various TLC developing systems are also presented.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 660467     DOI: 10.1002/jps.2600670626

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  2 in total

1.  Plasma concentrations of propranolol and 4-hydroxypropranolol during chronic oral propranolol therapy.

Authors:  L Wong; R L Nation; W L Chiou; P K Mehta
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

2.  Effects of acute and long-term beta-adrenoceptor blockade with propranolol on haemodynamics, plasma catecholamines and renin in essential hypertension.

Authors:  M A van Baak; T L Kho; H Thijssen; K H Rahn
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.